Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JCAR014 in Advanced CD19+ B-cell Malignancies
NCT01865617Phase 2Completed
- Sponsor
- Fred Hutchinson Cancer Center
- Start
- May 2013
- Primary completion
- Mar 2021
- Modality
- Gene Editing, Prophylactic Vaccines, Gene Silencing
- Countries
- 1
01
Overview
A Phase 2 trial of JCAR014 in acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), non-Hodgkin lymphoma (NHL), sponsored by Fred Hutchinson Cancer Center. Started May 2013; status: completed.
02
Drugs
JCAR014
03
Conditions
acute lymphoblastic leukemia (ALL)chronic lymphocytic leukemia (CLL)non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NCT01865617.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01865617.